23 Feb Flexion Therapeutics
Adam Muzikant, Ph.D., Chief Business Officer
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis. Our first product, ZILRETTA®, is the first and only FDA-approved extended-release, intra-articular injection for OA knee pain. Our pipeline includes FX201, an intra-articular gene therapy candidate being developed for symptomatic relief and disease modification in patients with knee OA. FX201 is designed to durably stimulate the production of an anti-inflammatory protein, IL-1Ra, whenever inflammation is present in the joint. Enrollment in a Phase I clinical trial with FX201 in patients with knee OA began in Q1 2020. We are also developing FX301, a locally delivered NaV1.7 inhibitor formulated for extended release from a thermosensitive hydrogel, for control of post-surgical pain. FX301 entered clinical trials in Q1 2021.